The present invention provides a compound having improved balance of S1P5 receptor agonistic activity against S1P1 receptor agonist activity, in order to develop a medicament useful for treatment of S1P5-mediated diseases, for example, neurodegenerative diseases such as schizophrenia, Bin Swanger's disease and the likes.A compound represented by the following general formula (V) is useful as therapeutic agents for S1P5-mediated diseases, for example, neurodegenerative diseases such as such schizophrenia and as Binswanger’s disease, because the balance of an S1P5 receptor agonistic activity against an S1P1 receptor agonist activity is improved.(In the formula, all symbols are as described in the specification)本發明為了開發在S1P5介入性疾病，例如，精神分裂症、賓斯旺格病等神經退化性疾病之治療上有用的醫藥品，提供一種S1P5受體作動活性相對於S1P1受體作動活性之平衡經改善的化合物。一種通式(V)所示之化合物由於改善了S1P5受體作動活性相對於S1P1受體作動活性的平衡，故可成為S1P5介入性疾病，例如，精神分裂症、賓斯旺格病等神經退化性疾病之治療劑。(式中，所有記號如說明書記載)
